Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brexit: UK Gov’t Says Retaining The EMA Cannot Be A “Line In The Sand” Matter

Executive Summary

The European Medicines Agency is important to the UK but the government cannot say it will be a non-negotiable point in future talks regarding the country’s departure from the EU.


Related Content

Brexit: EMA Has A Visit A Week From Potential Hosts
UK MPs On Brexit: EMA And MHRA Are ‘Completely Intermingled’
‘Standardized’ Comment From Brexit Minister Raises Hopes For Parallel EU/UK Drug Approval System
EMA Post-Brexit: 'It Can’t Stay In The UK' … Or Can It?